34

nanotimes

Companies

Facts

R

USNANO’s net profit in 2009 totaled 11.25 billion rubles ($368.6 million). The Corporation’s

net profit in the reporting period resulted mostly from income received on deposit of temporary available funds as recommended by the Ministry of Finance of the Russian Federation. RUSNANO’s independent investment income in the reporting period reached 13.53 billion rubles ($443.3 million). The corporation’s before-tax income in 2009 totaled 14.07 billion rubles ($461 million). The spending of the Corporation in 2009, including the returned amount of the asset contribution, totaled 106.94 billion rubles ($3.5039 billion), which is below the estimated levels.

Furthermore, Standard & Poor’s expects strong on- going state support to be provided to Russian Cor- poration of Nanotechnologies in the next few years. The agency expects a “high” probability of extraordi- nary timely government support if necessary. There- fore the outlook on RUSNANO was revised to stable from negative and affirmed the ‚BB+‘ long-term, ‚B‘ short-term, and ‚ruAA+‘ national scale ratings on RUSNANO.

http://www.rusnano.com

G

erman company sarastro has introduced a new technology for controlled release of active sub-

stances. It allows to equip compounds and coatings with biocides, flavours, scents or drugs in such a way that they are not released to the environment straight away but only at the time the substance is needed. sarastro is specialized in the development and mar- keting of biologically active surface functions.

http://www.sarastro-nanotec.com

S

electa Biosciences, Inc., a biopharmaceutical company developing synthetic nanoparticle vac-

cines, has raised $15 million in a Series C financing round. OrbiMed Advisors LLC led the round, with participation from existing investors Polaris Venture

Partners, Flagship Ventures, NanoDimension and

Leukon Investments. The Series C financing brings the total capital raised by Selecta over the past 15 months to more than $30 million. Proceeds from the Series C financing will be used to expand Selecta’s development of a new class of synthetic vaccines for prophylactic and therapeutic indications based on the company’s proprietary targeted Synthetic Vac- cine Particle (tSVP™) platform. The company’s lead product candidate will enter first-in-human clinical evaluation in 2011. The tSVP platform is based on

biodegradable polymeric nanoparticles that fully-

integrate all the vaccine components for targeting to immune cells for optimal cellular or humoral immune response.

http://www.selectabio.com

S

hocking Technologies, an embedded ESD solutions company, raised an additional $5.2 mil-

lion in its B-1 round completing the round at $13.2 million. The money will be used to speed the build out of manufacturing in the next several months.

“We are seeing increasing interest in our embedded ESD solutions from multiple top tier companies and in products from cell phones, portable electronics, memory devices and semiconductors it has become evident we need to scale faster to meet the demand. Our investors have been both enthusiastic and sup- portive of the need to grow faster and support our customers due to the successes in our initial trials. Shocking will increase our staff 33% over the next

10-04 :: April 2010